Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
19 Apr 2024
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/german-watchdog-approves-novos-acquisition-cardior-pharmaceuticals-2024-04-18/
26 Mar 2024
// REUTERS
https://www.reuters.com/markets/deals/novo-nordisk-buy-cardior-pharmaceuticals-up-11-bln-2024-03-25/#:~:text=COPENHAGEN%2C%20March%2025%20(Reuters),to%20strengthen%20its%20cardiovascular%20pipeline.
01 Dec 2022
// BUSINESSWIRE
08 Sep 2022
// BUSINESSWIRE
20 Jul 2022
// BUSINESSWIRE
06 Apr 2022
// BUSINESSWIRE
Details:
Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for heart failure.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CDR132L
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Novo Nordisk
Deal Size: $1,110.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition March 25, 2024
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Novo Nordisk
Deal Size : $1,110.0 million
Deal Type : Acquisition
Novo Nordisk to Acquire Cardior Pharmaceuticals, Enhancing Its Cardiovascular Pipeline
Details : Through the acquisition, Novo Nordisk expand its pipeline in cardiovascular disease by including Cardior’s lead compound CDR132L, currently in phase 2 clinical development for heart failure.
Brand Name : CDR132L
Molecule Type : Large molecule
Upfront Cash : Undisclosed
March 25, 2024
Details:
CDR132L is synthetic antisense oligonucleotide-based inhibitor directed against microRNA-132, that up-regulated in cardiac tissue of heart failure patients leading to expression of genes that are crucially involved in cardiac function thus leading to pathological remodeling.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CDR132L
Study Phase: Phase IIProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2022
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CDR132L is synthetic antisense oligonucleotide-based inhibitor directed against microRNA-132, that up-regulated in cardiac tissue of heart failure patients leading to expression of genes that are crucially involved in cardiac function thus leading to pat...
Brand Name : CDR132L
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
July 20, 2022
Details:
The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CDR132L
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Inkef Capital
Deal Size: $76.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 25, 2021
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inkef Capital
Deal Size : $76.0 million
Deal Type : Series B Financing
Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac ...
Details : The Series B proceeds will be used to fund the late-stage clinical development of Cardior’s lead program, CDR132L and the expansion of the company’s earlier-stage pipeline.
Brand Name : CDR132L
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 25, 2021
Details:
The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CDR132L
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2021
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.
Brand Name : CDR132L
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 29, 2021
Details:
The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: CDR132L
Study Phase: Phase IProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The study demonstrates that repeated treatment with its lead compound Cdr132 L is safe, improves cardiac function and reduces both ventricular as well as left atrial volumes in chronic heart failure.
Brand Name : CDR132L
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 22, 2020
Details:
In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.
Lead Product(s): CDR132L
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2020
Lead Product(s) : CDR132L
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Cardior Pharmaceuticals Demonstrates Reversal of Heart Failure with Lead Compound CDR132L
Details : In the in vivo study, Cardior´s compound CDR132L effectively prevented maladaptive growth and remodeling and restored cardiac function in a dose-dependent manner.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
January 31, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?